Loading stock data…
$78.90+0.37 (+0.47%)
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Kiniksa Pharmaceuticals International, plc in the Healthcare sector is trading at $79.50 with a market capitalization of $6.0B. Wall Street consensus targets $98.00 (8 analysts), implying a +23.3% move over the next 12 months. The stock is currently near its 52-week high of $82.94, remaining 37.9% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $243.60M↑ | $214.27M↑ | $202.13M↑ | $180.85M↑ | $156.80M |
| Gross Profit | $131.96M↑ | $117.89M↑ | $111.15M↑ | $97.29M↑ | $85.78M |
| Operating Income | $27.19M↓ | $29.27M↑ | $19.77M↓ | $24.02M↑ | $20.16M |
| Net Income | $25.43M↑ | $22.59M↑ | $14.20M↓ | $18.43M↑ | $17.83M |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...